F2 gene G20210A polymorphism and its relationship to plasma hemostasis activity in patients with acute coronary syndromes associated with type 2 diabetes
Abstract
Complex diseases, such as coronary heart disease and diabetes, are caused by the nonlinear interaction of numerous genetic and environmental risk factors. Characterization not only of candidate genes but also of complex interactions between them is obviously a more powerful approach to the study of such diseases. The inconsistency of data from various studies is explained by the fact that the genetic risk of coronary heart disease is not based on the action of a single gene, but on the interaction between several pathophysiological pathways controlled by several genes and other risk factors. The aim of the study was to determine the state of blood coagulation activity in patients with acute coronary syndrome with concomitant type 2 diabetes mellitus depending on the G20210A polymorphism of the F2 gene. Materials and methods: In the course of the study we examined 60 patients treated in the Department of Emergency Cardiology: 30 patients with acute coronary syndrome, 30 patients with acute coronary syndrome in combination with type 2 diabetes and 15 healthy individuals (control group). For molecular genetic analysis, DNA samples of patients isolated from venous blood by sorbent method were used. The G20210A polymorphism of the F2 gene was determined by the polymerase chain reaction using a two-primer system and ready-made reagents (Sintol, Russia) on an Applied Biosystems 7500. Statistical processing of the results was performed using SPSS-23. Results: After analyzing the data, we can conclude that the general trend of changes in plasma hemostasis in the group of patients with acute coronary syndrome intensified coagulation processes, but they did not depend on mutations in the F2 gene. Conclusions: Thus, in the group of patients with acute coronary syndrome, no significant relationship was found between coagulation parameters, anticoagulant system and G20210A polymorphisms.
References
Almawi, W. Y., Ameen, G., Tamim, H., Finan, R. R., & Irani-Hakime, N. (2004). Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. Journal of Thrombosis and Thrombolysis, 17(3), 199–205.
Hendy, O. M., Abd Al Moneam, E. L. H. A. M. Y., Allam, M., Soliman, S., Kamal, A., & Abd El Nasser (2011). Frequency of thrombotic gene mutations in diabetic patients with and without coronary artery disease. The Medical Journal of Cairo University, 79(2).
Hmimech, W., Idrissi, H. H., Diakite, B., Baghdadi, D., Korchi, F., Habbal, R., & Nadifi, S. (2016). Association of C677T MTHFR and G20210A FII prothrombin polymorphisms with susceptibility to myocardial infarction. Biomedical reports, 5(3), 361-366.
Inbal, A., Freimark, D., Modan, B., Chetrit, A., Matetzky, S., Rosenberg, N., Dardik, R., Baron, Z., & Seligsohn, U. (1999). Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood, 93(7), 2186–2190.
Jadaon, M. M. (2011). Epidemiology of prothrombin G20210A mutation in the Mediterranean region. Mediterranean journal of hematology and infectious diseases, 3(1).
Kaur, R., Das, R., Ahluwalia, J., Kumar, R. M., & Talwar, K. K. (2016). Genetic polymorphisms, biochemical factors, and conventional risk factors in young and elderly north Indian patients with acute myocardial infarction. Clinical and Applied Thrombosis/Hemostasis, 22(2), 178-183.
Lavigne-Lissalde, G., Sanchez, C., Castelli, C., Alonso, S., Mazoyer, E., Bal Dit Sollier, C., Drouet, L., Juhan-Vague, I., Gris, J. C., Alessi, M. C., & Morange, P. E. (2010). Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. Journal of Thrombosis and Haemostasis: JTH, 8(5), 942–949.
Lijfering, W., Middeldorp, S., Veeger, N., Hamulyák, K., Prins, M., Büller, H., & van der Meer, J. (2011). Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Phlebology, 26(5), 217-219.
Oros, M. M., Lutz, V. V., Pavlo, A. H., & Sitkar, A. D. (2020). Investigation of the influence of thrombophilic genes polymorphism, including serpin 1 (pai-i), fii, prothrombin and itgb3-β integrin, on the frequency of stroke in association with controllable risk factors for its occurrence. Wiad Lek, 73(3), 471-477.
Poort, S. R., Rosendaal, F. R., Reitsma, P. H., & Bertina, R. M. (1996). A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.
Rosendaal, F. R., Siscovick, D. S., Schwartz, S. M., Beverly, R. K., Psaty, B. M., Longstreth, W. T., Jr, Raghunathan, T. E., Koepsell, T. D., & Reitsma, P. H. (1997). Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood, 89(8), 2817–2821.
Wang, J. J., & Fang, M. Y. (2016). Effects of coagulation factors and inflammatory cytokines on development of acute myocardial infarction in patients younger than 60 years. Tropical Journal of Pharmaceutical Research, 15(4), 827-831.
Yamada, Y., Ichihara, S., & Nishida, T. (2008). Molecular genetics of myocardial infarction. Genomic medicine, 2(1-2), 7-22.
Zivelin, A., Mor-Cohen, R., Kovalsky, V., Kornbrot, N., Conard, J., Peyvandi, F., ... & Seligsohn, U. (2006). Prothrombin 20210G> A is an ancestral prothrombotic mutation that occurred in whites approximately 24 000 years ago. Blood, 107(12), 4666-4668.
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
